N-butyl-3-methyl-2-oxobutyramide | 99065-24-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: N-butyl-3-methyl-2-oxobutyramide
• 英文别名: Isopropyl-glyoxylsaeure-N-butyl-amid；N-butyl-3-methyl-2-oxobutanamide
• CAS: 99065-24-4
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: YXKQGLAPVLTODC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异腈基正丁烷 在 水 作用下， 生成 N-butyl-3-methyl-2-oxobutyramide
  参考文献：
  名称：

  Ugi,I.; Fetzer,U., Chemische Berichte, 1961, vol. 94, p. 1116 - 1121

  摘要：

  DOI：

文献信息

• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11124497B1

  公开（公告）日：2021-09-21

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Exemplary compounds provided include Formula II-I, where R3, RB are provided herein:

  该披露提供了具有战斗头的化合物及其在治疗医学疾病或紊乱，如病毒感染方面的用途。提供了制药组合物和制备各种带有战斗头的化合物的方法。这些化合物被认为能够抑制蛋白酶，如3C、CL-或3CL样蛋白酶。提供的示例化合物包括Formula II-I，其中R3、RB如下所示：
• Rearrangements of Trihalomethyl Ketones
  作者：Samuel Braverman、Marina Cherkinsky、E.V.K Suresh Kumar、Hugo E Gottlieb

  DOI：10.1016/s0040-4020(00)00360-4

  日期：2000.6

  competition between 1,2- vs. 1,3-elimination and nucleophilic substitution. Favorskii rearrangement was the preferred process, but in those cases where electronic or steric effects were present, nucleophilic substitution became dominant. No evidence of ketene formation was detected. The mechanism of formation of the various rearrangement products is discussed.

  制备了三卤代甲基酮，并根据1,2-消除1,3-消除和亲核取代之间的竞争对它们在碱性条件下的反应性进行了研究。Favorskii重排是首选方法，但是在存在电子或空间效应的情况下，亲核取代作用占主导地位。没有检测到乙烯酮形成的证据。讨论了各种重排产物的形成机理。
• INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
  申请人：Pardes Biosciences, Inc.

  公开号：US20210355111A1

  公开（公告）日：2021-11-18

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.